Stroke

Aspirin may be better preventive than ticlopidine in African-American patients

Published in Blood Weekly, July 3rd, 2003

Aspirin appears to be the better treatment than the antiplatelet drug ticlopidine for preventing recurrent stroke in black patients, according to a study in the Journal of the American Medical Association (JAMA).

"Blacks are disproportionately affected by stroke, yet they have been under-represented in clinical trials," the authors said. "Recommendations for stroke prevention have been based largely on trials that have included few black participants."

They noted that blacks are about two times more likely than most other individuals in the United States to die of or experience stroke.

Philip B. Gorelick, MD, MPH, from Rush...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry